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Opium poppy (Papaver somniferum) produces
medicinally important benzylisoquinoline alkaloids,
including the analgesics codeine and morphine,
in themorphinan pathway.We aligned three dioxyge-
nases thatwere recently discovered inP. somniferum
and subsequently identified the nonconserved
regions. Two of these enzymes, codeine O-deme-
thylase (PsCODM) and thebaine O-demethylase
(PsT6ODM), are known to facilitate regioselective
O-demethylation in morphinan biosynthesis. We
systematically swapped the residues that were non-
conserved between the PsCODM and PsT6ODM
sequences to generate 16 mutant PsCODM proteins
that couldbeoverexpressed inEscherichiacoli.While
wild-type PsCODM can demethylate both codeine
and thebaine, one engineered PsCODM mutant
selectively demethylates codeine. Use of this reengi-
neered enzyme in the reconstitution of morphine
biosynthesis could selectively disable a redundant
pathway branch and therefore impact the yields of
the downstream products codeine and morphine in
subsequent metabolic engineering efforts.
INTRODUCTION
Opium poppy produces an array of medicinally important benzy-
lisoquinoline alkaloids, including the analgesics codeine 10 and
morphine 11 (Figure 1) (Facchini, 2001; Facchini et al., 2005).
The biosynthesis of these alkaloids commences with the con-
densation of dopamine 1 and 4-hydroxyphenylacetaldehyde 2
to form (S)-norcoclaurine 3, which is further modified to form
(S)-reticuline 4, the pivotal biosynthetic intermediate of all benzy-
lisoquinoline alkaloids. (S)-reticuline 4 is subsequently converted
to thebaine 5, the intermediate at the entry point of the mor-
phinan alkaloid pathway. Two biosynthetic routes have been
proposed for the conversion of thebaine 5 to morphine 11 (Hagel
and Facchini, 2010). In the first route (route A; see Figure 1),
thebaine 6-O-demethylase (PsT6ODM) demethylates thebaine
5 at the 6 position to form neopinone 7, which spontaneously
isomerizes to form codeinone 8. Codeinone 8 is then enzymati-
cally reduced to yield codeine 10. Codeine O-demethylase674 Chemistry & Biology 19, 674–678, June 22, 2012 ª2012 Elsevier(PsCODM) demethylates codeine 10 at the 3 position to yield
morphine 11. Alternatively, in the second route (route B; see Fig-
ure 1), PsCODM demethylates thebaine 5 at the 3 position to
form oripavine 6. PsT6ODM catalyzes the second demethylation
of oripavine 6—this time at the 6 position—to formmorphinone 9,
which is then reduced to formmorphine 11. Morphinan alkaloids
thebaine 5, oripavine 6, codeine 10, and morphine 11 all accu-
mulate in Papaver somniferum, suggesting that both routes are
operative in vivo (Facchini, 2001; Facchini et al., 2005). Here
we demonstrate how exploiting natural enzyme variation through
systematically mixing and matching the nonconserved amino
acid regions of two demethylases (PsCODM and PsT6ODM)
has led to an enzyme with new specificity: a PsCODM mutant
that is highly selective for codeine. The unique selectivity of the
reengineered demethylase enzyme may allow us to explore
how closing the metabolic valve of route B and redirecting
substrate exclusively through route A (Figure 1) will impact
downstream product yields in this branched natural product
pathway.
RESULTS
Design of P. somniferum PsCODM Mutants
A clustal alignment of PsCODM, PsT6ODM, and PsDIOX2
(a P. somniferum 2-oxoglutarate/Fe(II)-dependent dioxygenase
for which the native substrate has not yet been identified) re-
vealed five specific regions where these dioxygenases differ
significantly at the amino acid level: A1 (residues 145–149), A2
(residues 150–152), B (residues 334–336), C1 (residues 338–
342), and C2 (residues 343 - 152). Lacking a crystal structure
of a P. somniferum dioxygenase, we built a homology model
of PsCODM based on the crystal structure of Arabidopsis
thaliana anthocyanidin synthase (AtANS), a structurally char-
acterized 2-oxoglutarate/Fe(II)-dependent dioxygenase with
moderate amino acid sequence similarity to PsCODM (32%
identity at the amino acid level) (Schwede et al., 2003; Wilmouth
et al., 2002). We employed SWISS-MODEL, an automated
protein homology-modeling server, to generate the model
(Figure 2) (Schwede et al., 2003). Key residues likely to be
involved in Fe(II)/2-oxoglutarate binding are highlighted in
the Supplemental Information (Figure S1A available online).
The five regions—grouped as follows, A1 and A2 (residues
145–152); B (residues 334–336); and C1 and C2 (residues
338–346)—were then mapped on to this homology model,
where they appeared to be located proximal to the anthocyanin
binding site (Figure 2).Ltd All rights reserved
Figure 1. Biosynthesis of Benzylisoquinoline Alkaloids in
P. somniferum
The biosynthetic pathways leading to morphine 11 via morphinone 9 and
codeine 10.
Figure 2. Homology Models of PsT6ODM and PsCODM Based on
the Crystal Structure of AtANS
PsT6ODM is indicated in green, and PsCODM is indicated in pink. The models
were created using SWISS-MODEL. Regions A1 and A2 (residues 145–152) are
shown in red, B (residues 334–336) is in yellow, and C1 and C2 (residues
338–346) are in blue.
See also Figures S1, S2, S3, and S4 and Tables S1 and S2.
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mutants are expressed at low levels. Therefore, in this study,
we focused our efforts on developing engineered PsCODM
enzymes. We systematically replaced the native PsCODM
sequence with the corresponding sequence from PsT6ODM atChemistry & Biology 19,the five nonconserved regions using standard site-directed
mutagenesis. In total, we constructed 16 PsCODM mutants
(Table 1).
Heterologous Expression of P. somniferum PsCODM
Mutants and In Vitro Activity Assay of PsCODMMutants
Dr. Jillian Hagel and Professor Peter Facchini (University of
Calgary, Calgary, Alberta, Canada) provided Escherichia coli
expression plasmids pQEDIOX1 and pQEDIOX3, which contain
the open reading frames of P. somniferum T6ODM and CODM,
respectively. Primers to design the mutant constructs are listed
in the Supplemental Information (Table S1). We adapted heterol-
ogous expression conditions for E. coli from a previously re-
ported protocol (Hagel and Facchini, 2010). Protein expression
of the majority of PsCODM mutants was robust (Figure S1B).
Only the A1A2*BC1C2 mutant (S149M L151F S152T mutant; the
asterisk designates the mutated region) was expressed at low
levels, perhaps due to improper folding. We screened each of
the mutant PsCODM enzymes with substrates thebaine 10 and
codeine 5 at a concentration of 0.25 mM. Detailed assay condi-
tions are provided in the Experimental Procedures.
Product formation was monitored using liquid chromatog-
raphy-mass spectrometry (LC-MS). LC-MS chromatograms of
representative in vitro enzymatic assays of wild-type and mutant
PsCODM enzymes are shown in the Supplemental Information
(Figure S2). These endpoint assays indicated that the majority
of the mutants lost O-demethylase activity toward both thebaine
5 and codeine 10 substrates. Out of the total of 16 mutants, only
two, A1 A2 B C1* C2 (E338G I340L L341V K342E) and A1 A2 B* C1
C2 (R334S R336S+T), retained O-demethylase activity toward
either thebaine 5 or codeine 10 (Figure S2). The A1 A2 B* C1 C2
mutant was similar to the wild-type enzyme in that it turned
over both thebaine 5 and codeine 10 to yield oripavine 6 and
morphine 11, respectively. The coelution of the wild-type674–678, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 675
Table 1. PsCODM Mutants that Were Constructed in This Study
A1 A2 B C1 C2 (Wild-type PsCODM)
1 A1* A2* B C1* C2*
2 A1* A2 B C1* C2*
3 A1* A2* B C1 C2*
4 A1* A2* B C1* C2
5 A1* A2* B C1 C2
6 A1* A2 B C1 C2*
7 A1* A2 B C1* C2
8 A1* A2 B C1 C2
9 A1 A2* B C1* C2*
10 A1 A2 B C1* C2*
11 A1 A2* B C1 C2*
12 A1 A2* B C1* C2
13 A1 A2* B C1 C2
14 A1 A2 B C1 C2*
15 A1 A2 B C1* C2
16 A1 A2 B* C1 C2
An asterisk indicates that the residues in that region were mutated to
those of PsT6ODM.
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thylation products suggests that the A1 A2 B* C1 C2 mutant
retained regiospecificity for the 3 position of thebaine 5 (Fig-
ure S2). In contrast, the A1 A2 B C1* C2 mutant displayed only
negligible O-demethylation activity for thebaine 5 but selectively
turned over codeine 10 (Figure S2). Since codeine 10 only
contains a methoxy group at the 3 position, the C3 regioselectiv-
ity of the A1 A2 B C1* C2 mutant is also clearly unchanged from
the wild-type PsCODM.
Competitive assay conditions with both thebaine 5 (0.25 mM)
and codeine 10 (0.25 mM) were also employed to assess the
activity of PsCODM mutants (Figure 3). Morphine 11 and oripa-
vine 6 products formed at a 4:1 ratio when wild-type PsCODM
was subjected to these assay conditions. Similarly, the A1 A2
B* C1 C2 mutant also yielded morphine 11 and oripavine 6 at
approximately a 4:1 ratio, though notably at lower concentra-
tions than the wild-type enzyme, indicating lower catalytic effi-
ciency for the mutated enzyme. However, while the A1 A2 B
C1* C2 mutant produced only negligible amounts of oripavine
6, morphine 11was produced at levels similar to those observed
with wild-type enzyme, confirming the stringent selectivity of the
A1 A2 B C1* C2 mutant.
Steady-State Kinetic Analyses of Wild-Type
P. somniferum PsCODM and Mutant A1A2BC1*C2
We measured the steady-state kinetic parameters of wild-type
PsCODM and mutant PsCODM A1A2BC1*C2 by monitoring the
rate of product formation. In total, we measured kinetic parame-
ters for the following combinations: (1) wild-type PsCODM with
codeine (kcat/KM = 9.54 3 10
7s1mM1 and KM = 72.3 ±
33.4 mM); (2) wild-type PsCODM with thebaine (kcat/KM =
1.523 108s1mM1 and KM = 216 ± 76.2 mM); and (3) PsCODM
mutant A1A2BC1*C2 with codeine (kcat/KM = 3.62x10
7s1mM1
and KM = 99.0 ± 22.4 mM). Notably, the mutant enzyme formed
only negligible amounts of the thebaine demethylation product676 Chemistry & Biology 19, 674–678, June 22, 2012 ª2012 Elsevierafter 4 hr even when substrate concentrations were as high
as 2,000 mM. Steady-state kinetic data are shown in the
Supplemental Information (Figure S3 and Table S2).
DISCUSSION
Here we have altered the substrate specificity of PsCODM, an
enzyme involved in the biosynthesis of morphinan alkaloids.
We identified regions for mutation by comparing three highly
similar dioxygenases from P. somniferum, two of which have
defined and distinct substrate and regioselective preferences.
By scanning the aligned sequences we identified five noncon-
served regions, A1, A2, B, C1, and C2 (Figure 2 and Figure S1A),
that we speculated could confer either the substrate or re-
gioselectivity of the dioxygenases in P. somniferum. To test
this hypothesis, we systematically swapped the amino acid
sequences of the A1, A2, B, C1, and C2 regions from thebaine 6
O-demethylase (PsT6ODM) into PsCODM. While most of the
interchanges of these regions yielded PsCODM mutants that
were catalytically inactive, replacement of the C1 region of
PsCODM with the C1 region of PsT6ODM led to a switch from
a wild-type enzyme that accepts two substrates—thebaine 5
and codeine 10—to a mutant enzyme that is selective for
codeine 10 exclusively. This PsCODM mutant, A1 A2 B C1* C2,
contains only four amino acid changes from wild-type PsCODM:
E338G, I340L, L341V, and K342E.
Although structural information is not yet available for these
demethylases, we could build a homology model for both wild-
type andA1A2BC1* C2mutantPsCODMbased on the anthocya-
nidin synthase enzyme docked with thebaine 5 (Figure S4). While
these computational results must be interpreted with caution,
docking studies suggest that the binding orientation of thebaine
differs substantially between the wild-type enzyme and the A1 A2
B C1* C2 mutant (Figure S4). It is interesting that the homology
model (Figure 2) also predicts that the C1 region switches from
an alpha helix in the wild-type enzyme to a random coil in the
codeine-specific mutant, suggesting that the mutation in the C1
region introduces changes to the PsCODM secondary structure.
The mutation in the C1* region appears to prevent productive
binding of the thebaine 5 substrate without greatly altering the
catalytic efficiency for codeine 10 (kcat/KM = 9.54 3 10
7
s1mM1 for wild-type, kcat/KM = 3.623 10
7 s1mM1 for mutant).
At the outset of this study, we hypothesized that the amino
acid differences between PsCODM, a C3 O-demethylase, and
PsT6ODM, a C6 O-demethylase, would control the distinct
regioselectivity of the demethylation reactions. Therefore, we
expected that swapping the non-conserved amino acid regions
of these two enzymes would alter the regioselectivity of the
mutated enzymes. However, the A1 A2 BC1* C2PsCODMmutant
retained C3 regioselectivity. Instead, the mutations altered the
substrate selectivity in an unpredictable manner. PsT6ODM
turns over thebaine 5 and oripavine 6, and PsCODM turns over
thebaine 5 and codeine 10. Despite both wild-type enzymes ac-
cepting thebaine 5, the introduction of residues from PsT6ODM
into PsCODM at the C1 position (Figure 2) yields a mutant
PsCODM enzyme that is selective for codeine 10. This change
in substrate specificity does not readily correlate with the
substrate specificity of the parent wild-type enzymes. Particu-
larly in the absence of experimental structural data, it is difficultLtd All rights reserved
Figure 3. Biochemical Activity of PsCODM
Enzymes
LC-MS traces of an in vitro enzymatic assay of
wild-type and selected mutant PsCODM enzymes
(1 mM final enzyme concentration) with 0.25 mM
thebaine 5 and 0.25 mM codeine 10 in Tris buffer
(100 mM Tris-HCl, 10% [v/v] glycerol, 14 mM
2-mercaptoethanol, pH 7.4) containing 10 mM
2-oxoglutarate, 10 mM sodium ascorbate and
0.5 mM iron (II) sulfate. Reactions were performed
at 30C for 4 hr. Mass-to-charge ratio (m/z) 286
corresponds to morphine 11; m/z 298 corre-
sponds to oripavine 6. LC-MS spectra are nor-
malized to the same y axis scale.
See also Figures S1, S2, S3, and S4 and Tables S1
and S2.
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PsCODM and how these changes impact substrate specificity.
Nevertheless, while this work highlights the difficulty of rational,
structure-based protein design, we successfully demonstrate
how sequence alignment of enzymes with subtle differences in
specificity can be used to readily generate swapped sequences
that are functionally distinct from naturally occurring wild-type
variations.
One goal of metabolic engineering is the removal of shunt or
redundant pathways that adversely impact production yields of
a desired compound (Pickens et al., 2011). This A1 A2 B C1* C2
PsCODMmutant may fulfill an engineering function by providing
ameans to shut off a redundant route (route B in Figure 1) in mor-
phinan biosynthesis. Because A1 A2 B C1* C2 PsCODM fails to
demethylate thebaine 5 to form oripavine 6, the first committed
step of route B, replacement of wild-type PsCODM with the A1
A2 B C1* C2 mutant would presumably force the morphine
pathway to proceed via route A. Notably, growers in India,
a major cultivator of licit opium, inadvertently counterselected
for P. somniferum cultivars low in oripavine 6 when selecting
for the highest seed quality and opium yields (Prajapati et al.,
2002), suggesting that low oripavine 6 production levels may
correlate with economically desirable traits. Therefore, in addi-
tion to assessing how knockouts of wild-type PsCODM and
PsT6ODM affect flux into morphine production, it will be of
interest to observe how using the PsCODM A1 A2 B C1* C2
mutant—which effectively sidesteps oripavine 6 production
by committing thebaine 5 to route A—instead of the wild-type
PsCODM enzyme would impact titers of codeine 10 and mor-
phine 11 (Prajapati et al., 2002). Moreover, substantial interest
lies in reconstituting morphinan alkaloid biosynthesis in yeast
and E. coli (Hawkins and Smolke, 2008; Minami et al., 2008;
Nakagawa et al., 2011). Mutants with altered specificity such
as PsCODM A1 A2 B C1* C2 could provide important building
blocks for these synthetic biology efforts.
SIGNIFICANCE
We have altered the substrate specificity of a morphinan
pathway enzyme codeine O-demethylase (PsCODM). OneChemistry & Biology 19,PsCODM mutant, mutant A1 A2 B C1* C2 (E338G I340L
L341V K342E), exhibits demethylase activity exclusively
toward codeine 10, whereas the wild-type PsCODM exhibits
demethylase activity with both codeine 10 and thebaine 5.
These results provide a starting point for rationalizing how
PsCODM and PsT6OD, two enzymes involved in morphinan
biosynthesis with 73% identity at the amino acid level, facil-
itate O-demethylation regioselectivity on separate sets of
substrates. In addition to providing insight into O-demethy-
lase substrate selectivity, this mutant could also be useful in
biotechnological efforts to provide P. somniferum strains
with augmented yields of codeine 10 and morphine 11 and
diminished titers of oripavine 6, an intermediate in a redun-
dant pathway branch that has been associated with poor
seed quality and low opium yields. In short, mutants with
enhanced enzyme selectivity will allow us to explore how
the targeted disruption of a redundant pathway branch
affects downstream product yields and may enable more
efficient production of these high value compounds. In
addition to the potential biotechnological applications of
this enzyme, these protein engineering efforts also provide
a starting point for understanding how the subtle sequence
differences of highly similar enzymes can impact substrate
and regioselectivity.
EXPERIMENTAL PROCEDURES
Construction of PsCODM Mutant Expression Plasmids
pQEDIOX1 (pQET6ODM) and pQEDIOX3 (pQECODM), which contain the open
reading frames of PsT6ODM and PsCODM, respectively, were provided by
Professor Peter Facchini and Dr. Jillian Hagel (University of Calgary). To obtain
the 16 CODM mutants (Table 1), site-directed mutagenesis (SDM) was per-
formed using the Stratagene QuikChange Site-Directed Mutagenesis
kit. SDM primers are listed in the Supplemental Information (Table 1). The
PsCODM mutant constructs were sequenced to verify the DNA sequence
and were subsequently transformed for expression into E. coli strain
SG13009 (QIAGEN) via electroporation using standard protocols.
Heterologous Expression of PsCODM Mutants
A single transformed E. coli colony (strain SG13009 [QIAGEN]) was inoculated
in 10 ml Luria-Bertani (LB) media supplemented with kanamycin (0.05 g/l) and
ampicillin (0.1 g/l) and incubated overnight at 37C with shaking at 225 rpm.674–678, June 22, 2012 ª2012 Elsevier Ltd All rights reserved 677
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ampicillin (0.1 g/l) was inoculated with an overnight culture (8 ml) and incu-
bated at 37C with shaking at 225 rpm until reaching an optical density 600
(OD600) of 0.6. Protein expression was induced by the addition of isopropyl
b-D-galactopyranoside (IPTG; final concentration 0.3 mM). Following induc-
tion, cells were incubated at 6C with shaking at 225 rpm for 24 hr. Cells
were harvested by centrifugation and lysed by sonication. The hexa-histidine-
tagged PsCODM mutants were purified using Talon colbalt affinity column
(Clontech) using the manufacturer’s protocols. Eluted enzyme was subse-
quently buffer-exchanged into Tris buffer (100 mM Tris-HCl, pH 7.4, 10%
[v/v] glycerol, and 14 mM 2-mercaptoethanol) and immediately assayed for
activity. These enzymes were not stable upon extended storage.
In Vitro Activity Assay of PsCODM Mutants
The in vitro activity assay protocol was adapted from a previous report (Hagel
and Facchini, 2010). Briefly, the assay for 2-oxoglutarate/Fe(II)-dependent
dioxygenase activity was performed using a 100 ml reaction mixture of
100 mM Tris-HCl (pH 7.4), 10% (v/v) glycerol, 14 mM 2-mercaptoethanol,
0.25 mM alkaloid(s), 10 mM 2-oxoglutarate, 10 mM sodium ascorbate,
0.5 mM FeSO4, and 1 mM purified enzyme. Assays were carried out for 4 hr
at 30C. Aliquots (25 ml) were quenched in 1ml methanol containing yohimbine
(500 nM) as an internal standard. The samples were centrifuged in a microcen-
trifuge (13,000 rpm, 5 min) to remove particulates and then analyzed by
LC-MS. Samples were ionized by ESI with a Micromass LCT Premier TOF
Mass Spectrometer. The LC was performed on an Acquity Ultra Performance
BEH C18, 1.7 mm, 2.1 3 100 mm column on a gradient of 10%–90% acetoni-
trile/water (0.1% formic acid) over 5 min at a flow rate of 0.6 ml/min. The
appearance ofmorphine 11 and oripavine 6wasmonitored by peak integration
and normalized to the internal standard. All chemicals were obtained from
a commercial source (Sigma Aldrich).
Steady-State Kinetic Assay of Wild-Type CODM and A1 A2 B C1* C2
Mutant
Assay components were used in the following final concentrations: pH 7.4
Tris-HCl (67 mM) containing 10% (v/v) glycerol and 14 mM 2-mercaptoetha-
nol, a-ketoglutarate (6.7 mM), sodium ascorbate (6.7 mM), iron (II) sulfate
(333 mM), and enzyme wild-type (4.1 mg/ml) or Enzyme Mutant (18 mg/ml), in
an assay volume of 150 ml. The enzyme concentrations were estimated by
Bradford assay. Assays were initiated by addition of iron sulfate and con-
ducted at 30C. Aliquots (25 ml) were quenched every 30 min from 1 to 3 hr
with 975 ml methanol containing 500 nM ajmaline as an internal standard. Prior
to analysis,methanol quenched samples were centrifuged in amicrocentrifuge
at 13,000 rpm for 5 min to remove any particulates. Liquid chromatography
was performed on an Acquity Ultra Performance BEH C18, 1.7 mm, 2.1 3
100 mm column. The gradient was 10%–90% acetonitrile over 4 min with
water and 0.1% formic acid in water as the second solvent. The flow rate
was 0.5 ml/min. We performed electrospray ionization (ESI) with a Micromass
LCT Premier TOF Mass Spectrometer in positive ionization V-mode.
Product accumulation wasmeasured to determine the kinetic parameters. A
standard curve for morphine, the demethylation product of codeine, was
constructed to determine the kinetic parameters of codeine demethylation.
However, oripavine, the demethylation product of thebaine, was unavailable;
therefore, hydromorphonone, which was available, was used as a surrogate.
Plotted experimental data were fit to a Michaelis-Menten curve using
SigmaPlot version 9.0. Experiments were duplicated or triplicated to ensure
reproducibility (Table S2).678 Chemistry & Biology 19, 674–678, June 22, 2012 ª2012 ElsevierSUPPLEMENTAL INFORMATION
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